The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment.
Monitoring the efficacy of highly active antiretroviral treatment (HAART) is crucial if disease progression and the emergence of viral mutants are to be avoided. Classical viral load monitoring is too expensive for large-scale use in resource-limited settings. Three alternative measures, CD4 count, total lymphocyte count (TLC) and haemoglobin, were evaluated as surrogate markers of treatment success (viral load below detection level) among 710 HIV-positive patients who started HAART in an HIV treatment centre in Belgium. TLC correlated well with changes in CD4 counts during HAART, but an increase in TLC alone was a poor predictor of treatment success. A combination of increases in both haemoglobin levels and TLC proved a reliable predictor of successful treatment outcome comparable to the increase in CD4 count, but its specificity and sensitivity were low.
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
E
E
Florence
C
C
Dreezen
W
W
Schrooten
M
M
Van Esbroeck
L
L
Kestens
K
K
Fransen
A
A
De Roo
R
R
Colebunders
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015415:Biomarkers; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D008297:Male; D010349:Patient Compliance; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D019562:Viral Load
D015415:Biomarkers